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Abstract
Rhenium(V) oxo complexes of general formula [ReO(OMe)(N^N)Cl2], where N^N = 4,7-
diphenyl-1,10-phenanthroline, 1, or 3,4,7,8-tetramethyl-1,10-phenanthroline, 2, effectively kill 
cancer cells by triggering necroptsosis, a non-apoptotic form of cell death. Both complexes evoke 
necrosome (RIP1-RIP3)-dependent intracellular ROS production and propidium iodide uptake. 
The complexes also induce mitochondrial membrane potential depletion, a possible downstream 
effect of ROS production. Apparently, 1 and 2 are the first rhenium complexes to evoke cellular 
events consistent with programmed necrosis in cancer cells. Furthermore, 1 and 2 display low 
acute toxicity in C57BL/6 mice and reasonable stability in fresh human blood.
Introduction
Cancer is a leading cause of death and suffering throughout the world and continues to 
impose a huge socio-economic burden on society. According to the latest statistics released 
by the World Health Organization, an estimated 8.2 million cancer-related deaths occurred 
in 2012, a 0.6 million increase from the previous estimation in 2008.1 With the global cancer 
burden rising, the development of new cancer treatments is crucial. Since the discovery of 
their antineoplastic properties in 1969, platinum drugs such as cisplatin, oxaliplatin, and 
carboplatin have become a mainstay chemotherapy for cancer.2,3 Their use, however, is 
limited by side effects and inherent or acquired resistance.4–6 These limitations have driven 
the search for new treatments, including investigations of other transition metal compounds. 
Many ruthenium, osmium, titanium, copper, iron, and other metal compounds have been 
tested for their anticancer activity, and some of the most promising candidates have been 
studied clinically.7
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Several rhenium-based compounds have been employed as in vitro and in vivo imaging 
agents, but in-depth studies exploring their anti-proliferative properties are relatively rare.8,9 
The most active rhenium compounds reported to date contain Re(I)-carbonyl centers bound 
to mono-, di-, tri-dentate ligands.10–14 This class of compounds are proposed to induce their 
cytotoxic effects through covalent interactions with DNA bases and/or protein side chains. A 
number of photolabile rhenium(I) derivatives that trigger cell death upon irradiation have 
also been devised.15–17 These complexes offer temporal and spatial control over activation 
and therefore could be useful in overcoming systemic toxicity. Recently, octahedral Re(IV) 
complexes bearing polypyridyl ligands were discovered to exhibit potent in vitro 
antiproliferative activity against breast, ovarian, and prostate cancer cells.18 The complexes 
were hypothesized to interact with nuclear DNA upon hydrolysis, inducing apoptotic cell 
death. The anticancer potential of dinuclear rhenium compounds has also been 
investigated.19–21 In addition to displaying promising anticancer activity, paddle-wheel 
dirhenate(III) complexes have attractive pharmacological features such as low neuro-, 
hepato- and nephrotoxicity.21–24 Dirhenate(III) units with propionate ligands and quadruple 
Re-Re bonds have varying degrees of efficacy in sarcoma-, leukemia- and melanoma-
bearing mice models.25 Subsequent studies found that the anticancer activity of the rhenium 
clusters depends on the identity and orientation of the ligands around the two rhenium(III) 
centers rather than the presence of a quadruple bond. Remarkably, dinuclear rhenium(III) 
analogues bearing alkylcarboxylates and zwitterionic aminocarboxylate ligands inhibited 
tumor growth by up to 60% in Wistar rats inoculated with tumor carcinoma Guerink (T8) 
cells. Furthermore when combined with cisplatin, the rhenium(III) clusters completely 
inhibited tumor progression.21–24,26 Dirhenate(III) complexes are also regarded as 
promising modulators of cisplatin. According to in vitro and in vivo studies, carboxylate-
bridges dirhenate(III) complexes stabilized red blood cells (RBC) against haemolysis, 
thereby diminishing dose-limiting toxicity associated with cisplatin.21–24,27
Many clinically used anticancer agents act by targeting and damaging nuclear DNA, 
eventually leading to apoptosis.28–31 Cytotoxic compounds may also kill cells through non-
apoptotic cell death pathways such as necrosis.32–34 Although necrosis was previously 
believed to be a random, unregulated process, it is now understood that programmed 
necrosis, also known as necroptosis, does occur in certain cell types.35 Necroptosis is 
activated by the formation of a complex between receptor interacting protein (RIP) kinases, 
RIP1 and RIP3.36 The RIP1-RIP3 complex, also known as a necrosome, is thought to 
modulate oxidative stress and generate mitochondrial reactive oxygen species (ROS) 
capable of inducing bioenergetics-related cell death.37 The relationship between ROS 
production and necroptotic cell death is poorly understood, although some reports link RIP1 
and ROS-induced cell death.38 Owing to the persistent use of apoptosis-inducing anticancer 
drugs, many cancers have evolved resistance to apoptosis.39–41 Therefore chemotherapies 
capable of inducing non-apoptotic cell death such as necroptosis warrant further 
investigation. Here we present the synthesis, characterization, and cell-based studies of two 
necroptosis-inducing rhenium(V) oxo complexes.
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Results and Discussion
Synthesis and Characterization
The rhenium(V) oxo complexes 1 and 2 were prepared by the reaction of [ReOCl3(PPh3)2] 
with 1.5 equivalents of the corresponding bidentate ligand in methanol (Scheme 1). The 
complexes were isolated in reasonable yields as pale green solids and fully characterized by 
NMR and IR spectroscopy, and ESI-MS spectrometry. The purity of the complexes was 
confirmed by elemental analysis. Variable-temperature 1H NMR spectroscopic studies in 
DMSO revealed the complexes to be stable and remain intact at elevated temperatures (up to 
75 °C, see Figure S1).
The cyclic voltammograms of 1 and 2 display only a single irreversible reduction within the 
potential window spanning −1.00 to 1.00 V versus Fc/Fc+ (Figure S2A & B). This event is 
ascribed to the two-electron reduction of the metal center in each complex to form, initially 
at least, a Re(III) product. The more negative cathodic peak potential of 2, −1.48 V, 
compared to that of 1, −1.32 V, is consistent with the more electron donating nature of the 
3,4,7,8-tetramethyl-1,10-phenanthroline ligand, which better stabilizes the Re(V) oxidation 
state. To further rationalize the different redox potentials of the two compounds, DFT 
calculations were performed at the uPBEPBE/LANL2DZ level of theory in Gaussian 03.42 
Solvent effects of DMSO were included implicitly through the self-consistent reaction field 
approach, as implemented in the default PCM model. The calculations suggested that both 
compounds preferentially adopt a low-spin configuration, which is significantly lowerer in 
energy than the corresponding high-spin one (Figure S2C & D). Partial atomic charges were 
calculated by means of Mulliken population analysis.43 As shown in Table S1, the 
calculated HOMO energy of 2 is higher than that of 1, which is consistent with observed 
redox potentials.44 The Mulliken charges on the Re(V) atom also predict that 2 has a lower 
redox potential than 1. These results can be attributed to the stronger electron-withdrawing 
effect of the phenyl group (χp = 2.49),45 which can presumably stabilize reduced 1. Overall, 
the electrochemical studies and calculations shows that the reduction potential of 
rhenium(V)-oxo complexes such as 1 and 2 can be tuned by subtle ligand modifications.
The lipophilicity of the rhenium(V)-oxo complexes (1 and 2) was determined by measuring 
the extent to which they partition between octanol and water, Po/w or P. The experimentally 
determined log P values are 1.20 for 1, and 0.95 for 2. The hydrophobic character of the 
rhenium(V)-oxo complexes suggests that they will be taken up well by cells.
In Vitro Potency
In vitro effect of rhenium(V) oxo complexes 1 and 2 toward a panel of human cell lines was 
determined by the colorimetric MTT [[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. Cisplatin was also included as a control. The IC50 values or concentration 
required to induce 50% cell death, were derived from dose-response curves and are 
summarized in Table 1. Compounds 1 and 2 display nanomolar potency toward cancer cells, 
with good selectivity over normal fibroblast cells (up to 10-fold). The cytotoxicity of the 
rhenium complexes was significantly higher than that of cisplatin for the cell lines tested. 
Notably, 1 displayed 34-fold higher toxicity for lung carcinoma A549 cells compared to 
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cisplatin. Furthermore, the rhenium complexes are not cross-resistant with cisplatin, as 
demonstrated by their ability to kill cisplatin-resistant ovarian carcinoma cells (A2780CP70) 
with up to 15-times better efficacy than cisplatin-sensitive cells (A2780).
Given the ability of 1 and 2 to selectively kill ovarian cisplatin-resistant over sensitive cells, 
we evaluated their efficacy against other cisplatin-resistant cell lines derived from tissues 
such as HT-29 (colorectal adenocarcinoma), MDA-MB-231 (breast adenocarcinoma), PC-3 
(prostate adenocarcinoma), MCF-7 (breast adenocarcinoma), and DU 145 (prostate 
carcinoma). The rhenium complexes displayed nanomolar and sub-micromolar toxicities 
toward the cisplatin-resistant cells (Table 2). Remarkably, 1 and 2 killed colorectal 
adenocarcinoma HT-29 cells over 300-fold better than cisplatin. Although cisplatin is one of 
the most successful broad-spectrum anticancer drugs in clinical use, several tumors exhibit 
resistance. A plethora of molecular mechanisms account for cisplatin resistance, including 
reduced intracellular accumulation, increased sequestration by scavengers, efficient DNA 
repair, and deregulation of proteins involved in the DNA damage and apoptotic cell death 
pathways.47 Therefore compounds such as 1 and 2, which can overcome cisplatin-resistance, 
hold significant therapeutic potential. To further investigate this potential, cytotoxicity 
studies were conducted with quiescent A549 cells (Table 2). The potency of 1 and 2 toward 
quiescent A549 cells was over 40-fold less than toward proliferating A549 cells. This result 
highlights the ability of 1 and 2 to selectively kill fast growing cancer cells.
Cellular Mechanism of Action and Mode of Cell Death
To gain insight into how the rhenium complexes induce cell death, 1 and 2 were analyzed by 
a recently developed functional strategy employing a RNAi signature assay to predict the 
mechanism of cytotoxic drug action.48–50 This RNAi-based methodology relies on a 
fluorescence competition assay with lymphoma cells that are partially infected with eight 
distinct short hairpin RNAs (shRNAs). shRNA-bearing cells will either enrich or deplete 
relative to the uninfected population based on the survival advantage or disadvantage 
conferred by a given shRNA. The responses of these cells compose signatures, which have 
been obtained from all classes of clinically used cytotoxic agents. These signatures comprise 
a reference set which is then informatically classified by a probabilistic K-nearest neighbors 
algorithm to determine whether a new compound belongs to a class in the reference set or 
requires a new category not yet represented. Neither 1 nor 2 classified as belonging to any 
category of drug mechanism present in the reference set and thus represent novel 
mechanisms of drug action (Figure 1).
In order to determine the cell killing mechanism of 1 and 2, we carried out cytotoxicity 
studies in the presence of apoptosis and necrosis inhibitors. Upon addition of z-VAD-FMK, 
a potent inhibitor of caspase-mediated apoptosis,51 the ability of 1 and 2 to kill A549 cells 
remained largely unaltered, indicative of a non-apoptotic cell death program (Figure 2A). By 
contrast, the IC50 values for known apoptosis-inducing agents such as etoposide and 
cisplatin increased significantly (t test, p < 0.05) in the presence of the inhibitor (Figure 2A). 
Immunoblotting studies showed that proteins implicated in the apoptotic cell death pathway, 
namely, cleaved-caspase 7 and 9, were not detected in 1- and 2-treated A549 cells (100 – 
400 nM for 72 h; Figure S3), providing further evidence for a non-apoptotic program. We 
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next investigated the possibility that 1- and 2-induce necroptosis. Necroptosis is a well 
regulated mode of cell death that is different from unregulated necrosis and apoptosis.35 
Unlike unregulated necrosis, which can be induced by H2O2 or heat, necroptosis relies on 
the interaction of protein kinases, RIP1 (receptor-interacting protein 1) and RIP3 (receptor-
interacting protein 3), to initiate cell disintegration. This process can be blocked by 
necrostatin-1, a potent RIP1 kinase inhibitor.52,53 To determine whether 1 and 2 induced 
necroptosis and/or uncontrolled necrosis, cytotoxicity studies were conducted in the 
presence of necrostatin-1 (60 μM) and IM-54 (10 μM), an inhibitor of H2O2-induced 
necrosis.54 Co-incubation with necrostatin-1 markedly decreased the toxicity of 1 and 2 (t 
test, p < 0.05) against A549, PC-3, and HT-29 cells (Figures 2B and S4). A similar effect 
was also observed for shikonin, a naturally occurring compound known to induce 
necroptosis in certain cell types (Figure S4A).38 In contrast, co-treatment with IM-54 did not 
significantly affect the toxicity of 1 and 2 (Figure 2B). Taken together, the cytotoxicity data 
suggest that 1 and 2 induce RIP1-RIP3 (necrosome) mediated necroptosis, rather than 
uncontrolled necrosis or apoptosis. Immunoblotting studies revealed that the overall 
expressional level of RIP1 and RIP3 in A549 cells remained unchanged with increasing 1 
and 2 dosages (Figure S3). Therefore 1- and 2-induced cell death relies on RIP1-RIP3 
complex formation and not on the expressional levels of the individual protein kinases. RIP1 
can also form a cytosolic complex with Fas-associated death domain (FADD) and caspase 8, 
known as a ripoptosome, to initiate apoptosis (through caspase 8 cleavage).55–57 
Immunoblotting studies showed that FADD and cleaved caspase 8 expression remained 
unaltered with increasing 1 and 2 concentration (Figure S3), indicating that ripoptosome 
formation was not responsible for 1- and 2-induced cell death. This finding is consistent 
with the fact that 1- and 2-treated A549 cells do not undergo apoptosis.
Characterization of Necroptotic Features
Having established that necrosome formation is a determinant of 1 and 2 activity, we 
performed additional studies to understand the cascade of events leading from necrosome 
formation to cell death. Necrosomes generate abnormally high levels of mitochondrial 
reactive oxygen species (ROS),58–60 leading to ATP depletion and eventual degradation of 
the mitochondrial membrane potential.61,62 With this fact in mind, we quantified 
intracellular ROS production by flow cytometry using 6-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA), a well-established ROS indicator. A549 
cells incubated with 1 and 2 (20 μM for 12 h) displayed markedly higher levels of ROS than 
untreated control cells (Figure 3A & B). A549 cells dosed with H2O2 (1 mM for 1 h, ROS-
inducer) and shikonin (20 μM for 12 h, necroptosis-inducer) also exhibited significantly 
higher levels of measurable ROS than untreated cells (Figure 3C & 3D). Remarkably, 1- and 
2-induced ROS production was attenuated in the presence of necrostatin-1 (60 μM) (Figure 
3A & B), suggesting that the RIP1-RIP3 kinase complex plays a role in modulating 
intracellular ROS production.
The effect of 1 and 2 on the mitochondrial membrane potential was assessed by flow 
cytometry, using the JC-1 assay (5,5′,6,6′-tetrachloro-1,1′3,3′-tetraethyl benzimidazolyl 
carbocyanine iodide).63,64 JC-1 is a cationic lipophilic dye that localizes in the mitochondria 
of healthy cells as red-emitting aggregates. If the mitochondrial membrane potential is 
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disrupted, JC-1 forms green-emitting monomers. A549 cells incubated with 1 and 2 (20 μM 
for 12 h) displayed increased green fluorescence compared to untreated cells, indicative of 
mitochondrial membrane disruption (Figure S5A & B). A similar result was observed for 
A549 cells dosed with carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (5 μM for 12 
h), a known mitochondrial membrane depolarizer (Figure S5C), and shikonin (20 μM for 12 
h), a necroptosis inducing agent (Figure S5D). Notably, 1- and 2-induced mitochondrial 
membrane depletion was amplified with necrostatin-1, suggesting that 1 and 2 may 
inherently target mitochondria and induce mitochondrial dysfunction, independent of RIP1-
RIP3 formation. This result could explain the high residual toxicity (>1 μM) observed for 
A549 cells co-incubated with the rhenium complexes (1 and 2) and necrostatin-1 (Figure 
2B).
Intracellular ROS production and mitochondrial membrane depletion contribute to 
necroptosis.61,62 Cells undergoing necroptosis display necrosis-like morphological features 
such as loss of cell membrane integrity, increase in organelle and cell volume (oncosis), and 
intact nuclear membrane.65–67 To further test whether 1- and 2-treatment is able to trigger 
necroptosis, Hoechst 33258/propidium iodide (PI) double staining was carried out to 
determine nuclear membrane morphology and integrity. Hoechst 33258 is a DNA minor 
groove binder that is routinely used to visualize the nucleus without the need for cell 
permeabilization.68 When used without cell permeabilization agents, PI stains the nuclei of 
necrotic cells.69 Early stage apoptotic and normal cells maintain cell membrane integrity and 
thus are not stained by PI. A549 cells were treated with 1 and 2 (20 μM for 12 h), incubated 
with Hoechst 33258 and PI, and imaged using a fluorescent microscope. Untreated A549 
cells exhibited bright blue nuclei, owing to Hoechst 33258 uptake (Figure 4A). Cells 
incubated with 1 and 2 displayed pink nuclei, owing to Hoechst 33258 and PI uptake, which 
is consistent with necroptosis (Figure 4B & C). Furthermore 1- and 2-treated cells showed 
clear signs of plasma membrane disintegration with undamaged nuclei. A549 cells co-
incubated with 1 or 2 and necrostatin-1 (60 μM for 12 h) were unstained by PI suggesting 
that necrostatin-1 is able to block 1- and 2-induced necroptosis (Figure 4E & F). Overall, the 
microscopy data suggest that necrosome formation contributes to the necrosis-like 
morphological features observed upon 1- and 2-treatment. To further validate this result, 
A549 cells were treated under the same conditions as above, stained with PI, and analyzed 
by flow cytometry. Complementary to the microscopy results, 1- and 2-treated cells 
expressed higher PI uptake compared to untreated control cells, indicative of necrotic cell 
death (Figure S6A & B). The flow cytometry data also showed that necrostatin-1 could 
block 1- and 2-mediated PI uptake. Additional studies showed that pre-treatment of A549 
cells with N-acetylcysteine (3mM for 1 h), a ROS inhibitor, significantly decreased 1- and 
2-induced PI uptake (Figure S6C & D). This result suggests that intracellular ROS 
generation is an integral part of the necroptotic mechanism of action of 1 and 2.
PARP-1- and p53-Independent Necroptosis
Apart from necrosome formation, necroptosis can also result from the overactivation of 
poly(ADP–ribose) polymerase (PARP-1).66,67 PARP-1 is a nuclear enzyme that is involved 
in DNA repair and transcriptional regulation.70 DNA damage can trigger PARP-1 activity, 
resulting in ATP and NAD depletion and bioenergetic-mediated cell death.71 To determine 
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whether PARP-1 activity is a factor in 1- and 2-mediated cell death, cytotoxicity assays were 
conducted with wild-type mouse embryonic fibroblast cells (MEFs PARP-1+/+) and the 
corresponding PARP-1-null cells (MEFs PARP-1−/−). The IC50 values for 1 and 2 were 
similar for MEFs PARP-1+/+ and MEFs PARP-1−/− cells, indicating that 1 and 2-induced 
necroptosis is independent of PARP-1 function (Figure 5A). This result is consistent with 
immunoblotting studies, which revealed that 1- and 2-treatment did not upregulate canonical 
markers of DNA damage such as the phosphorylated forms of H2AX γH2AX) and CHK2 
(Figure S7). Recently, p53 has also been reported to play a role in necroptosis. p53 induces 
cathepsin Q, a lysosomal protease that cooperates with ROS to execute necrosis.72 To 
investigate whether p53 might play a role in 1- and 2-mediated necroptosis, cytotoxicity 
studies were conducted with HCT116 p53+/+ and HCT116 p53−/− cells. The potency of 1 
and 2 was statistically similar for HCT116 p53+/+ and HCT116 p53−/− cells, indicating that 
1 and 2 induce necroptosis in a manner that is independent of p53 (Figure 5B). This 
concludion is consistent with the RNAi signatures, which reveal that p53 is not important in 
the cellular response evoked by the complexes, especially for 1. Apart from the implications 
of this result on the mechanism of action of 1 and 2, it is clinically very appealing because 
p53 is mutated, defective, or inactivated in several chemoresistant cancers.
Cell Cycle Analysis
To gain a more complete understanding of the cellular response evoked, DNA-flow 
cytometric studies were conducted to determine the effect of 1 and 2 on the cell cycle. A549 
cells were treated with 1 or 2 (2 μM) and the cell cycle was determined over the course of 72 
h (Figure S8). After 24 h treatment, both complexes stalled the cell cycle at the G1-phase. 
Cells treated with 1 remained stalled at the G1-phase after 48 h. Upon further incubation (72 
h), large populations of cell debris were detected (32%), indicative of cell death. Cells 
incubated with 2 for 48 h and 72h also displayed large populations of debris (26 and 38% 
respectively). G1-phase cell cycle arrest followed by immediate cell death is characteristic 
of programmed necrosis.73,74
In Vivo Toxicity and Stability in Whole Human Blood
Given the impressive in vitro data acquired for 1 and 2, an in vivo study was conducted with 
C57BL/6 mice to determine acute toxicity and possible side effects. Single doses of 1 and 2 
(3, 7, 11, 15, 20, 36 mg/ kg) in saline, were administered by intra-peritoneal injection. The 
mice were then monitored for signs of pain, distress, and weight loss for 6 days post-
treatment. The compounds exhibited no toxicity in mice, as gauged by a lack of weight loss 
after treatment. The change in weight of mice after a single dose of 1 and 2 at the maximum 
solubility of the complexes (36 mg/ kg) is depicted in Figure S9. A single 30 mg/ kg dose of 
cisplatin induces acute nephrotoxicity in C57BL/6.75 The in vivo data highlight the 
relatively low toxicity of 1 and 2 compared to cisplatin in C57BL/6 mice. The 
pharmacological toxicity profile of 1 and 2 is very appealing in terms of further pre-clinical 
studies.
The stability of biologically active compounds in human blood is vitally important for their 
potential application in clinical settings. We therefore investigated the stability of 1, in 
whole human blood using a recently developed protocol.76 This method exploits the ability 
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of octanol to extract hydrophobic metal complexes such as 1. The rhenium complex, 1 (500 
μM) was incubated with fresh human blood at 37 °C and aliquots were extracted into octanol 
at various time points. The amount of 1 in the octanol extracts (corresponding to unreacted 
1) was measured by graphite furnace atomic absorption spectroscopy (GFAAS). The data 
present in Figure S10, revealed that the half-life of 1 in human blood is 29.1 min, 
comparable to that reported for cisplatin (t1/2 = 21.6 min).77
Conclusion
Two rhenium(V) oxo complexes were prepared and their in vitro properties were 
investigated. The complexes selectively kill cancer cells over normal cells and display 
markedly higher cell toxicity than cisplatin. Remarkably, 1 and 2 display two orders of 
magnitude higher toxicity than cisplatin against colorectal adenocarcinoma cells. Cells 
treated with 1 and 2 displayed features consistent with programmed necrosis (necroptosis), 
including RIP1-RIP3 dependent intracellular ROS production, cell membrane disruption, PI 
uptake, mitochondrial damage, and G1 cell cycle arrest. Given the inherent and/or acquired 
resistance of tumors toward apoptosis-inducing chemotherapies, compounds such as 1 and 2, 
capable of killing cancer cells through necroptosis, are highly sought after when selecting 
preclinical drug candidates for chemoresistant malignancies.
Experimental Details
Material
All synthetic procedures were performed under normal atmospheric conditions without 
exclusion of oxygen or moisture. The bidentate aromatic ligands 4,7-diphenyl-1,10-
phenanthroline and 3,4,7,8-tetramethyl-1,10-phenanthroline were purchased from Sigma 
Aldrich and used as received. ReOCl3(PPh3)2 was prepared as previously reported.78 The 
synthesis of 1 has been reported previously,79 but the procedure reported here is novel. 
Analytical grade acetone and dichloromethane were used as solvents.
Physical Measurements
NMR measurements were recorded on a Bruker 400 MHz spectrometer in the MIT 
Department of Chemistry Instrumentation Facility (DCIF) at 20 °C. 1H and 13C{1H} NMR 
chemical shifts were referenced internally to residual solvent peaks or relative to 
tetramethylsilane (SiMe4, δ = 0.00 ppm). Fourier transform infrared (FTIR) spectra were 
recorded with a ThermoNicolet Avatar 360 spectrophotometer upon preparation of the 
samples as KBr disks. The spectra were analyzed using the OMNIC software. Graphite 
furnace atomic absorption spectrometry was carried out using a Perkin-Elmer AAnalyst600 
GFAAS.
Synthesis of [ReO(OMe)(4,7-diphenyl-1,10-phenanthroline)Cl2] (1)
[ReOCl3(PPh3)2] (63.8 mg, 0.08 mmol) was suspended in methanol (15 mL) and heated to 
50 °C. To this mixture was added a methanolic solution (5 mL) of 7-diphenyl-1,10-
phenanthroline (34.0 mg, 0.10 mmol). The resultant mixture was heated under reflux for 24 
h to give a deep purple solution with a pale green precipitate. The precipitate was filtered, 
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washed with hot methanol, cold methanol, and diethyl ether. The rhenium(V) oxo complex 
was isolated as a pale green solid. Yield: 19.8 mg (37%). Mp 247 °C (dec). 1H NMR (400 
MHz, DMSO-d6): δ 10.08 (d, 2H), 8.48 (d, 2H), 8.31 (s, 2H), 7.83 (m, 4H), 7.73 (m, 6H), 
2.56 (s, 3H). IR (KBr, cm−1): 941.51 (Re=O), 508.42 (Re-OMe). ESI-MS (MeOH/ DMSO): 
m/z. 605.0 ([M-OMe]+, calcd. 605.0). Anal. Calcd. for 1, C25H19Cl2N2O2Re: C, 47.17; H, 
3.01; N, 4.40. Found: C, 46.79; H, 3.05; N, 4.35.
Synthesis of [ReO(OMe)(3,4,7,8-tetramethyl-1,10-phenanthroline)Cl2] (2)
[ReOCl3(PPh3)2] (50.0 mg, 0.06 mmol) was suspended in methanol (15 mL) and heated to 
50 °C. To this mixture, a methanolic solution (5 mL) of 3,4,7,8-tetramethyl-1,10-
phenanthroline (21.85 mg, 0.09 mmol) was added. The resultant mixture was heated under 
reflux for 24 h to give a deep purple solution with a pale green precipitate. The precipitate 
was filtered, washed with hot methanol, cold methanol, and diethyl ether. The rhenium(V) 
oxo complex was isolated as a pale green solid. Yield: 14.8 mg (41%). Mp > 276 °C 
(gradual darkening and decomposition). 1H NMR (400 MHz, DMSO-d6): δ 9.69 (s, 2H), 
8.60 (s, 2H), 2.99 (s, 6H), 2.74 (s, 6H), 2.36 (s, 3H). IR (KBr, cm−1): 954.85 (Re=O), 492.85 
(Re-OMe). ESI-MS (MeOH/ DMSO): m/z. 509.0 ([M-OMe]+, calcd. 509.0). Anal. Calcd. 
for 2, C17H19Cl2N2O2Re: C, 37.78; H, 3.54; N, 5.18. Found: C, 37.76; H, 3.63; N, 4.99.
Electrochemistry
Electrochemical experiments were performed at room temperature using a VersaSTAT3 
potentiostat from Princeton Applied Research operated with the V3 Studio software. Cyclic 
voltammetry was performed using a three-electrode system comprising a glassy carbon 
working electrode, a platinum wire auxiliary electrode, and a silver wire pseudo-reference 
electrode. Potentials were referenced internally to the ferrocene/ferrocenium redox couple. 
Solutions of 1 and 2, at concentrations of approximately 2 mM, were prepared in DMSO 
containing 0.2 M tetra-n-butylammonium hexafluorophosphate. All solutions were sparged 
with nitrogen for 5 min prior to measurement. Voltammograms were obtained on quiescent 
solutions at a scan rate of 200 mV/s.
Cytotoxicity MTT assay
The colorimetric MTT assay was used to determine the toxicity of 1, 2, and cisplatin. Cells 
(2 × 103 cells/well) were seeded in a 96-well plate. After incubating the cells overnight, 
various concentrations of platinum as determined by GF-AAS (0.3–100 μM) were added and 
incubated for 72 h (total volume 200 μL). Cisplatin was prepared as a 5 mM solution in PBS 
and diluted using media. 1 and 2 were prepared as 10 mM solutions in DMSO and diluted 
using media. The final concentration of DMSO in each well was 0.5% and this amount was 
also present in the untreated control. After 72 h, the medium was removed, 200 μL of a 0.4 
mg/mL solution of MTT in DMEM, RPMI or, McCoy’s 5A was added, and the plate was 
incubated for an additional 1–2 h. The DMEM/MTT, RPMI/MTT, or McCoy’s 5A/MTT 
mixture was aspirated and 200 μL of DMSO was added to dissolve the resulting purple 
formazan crystals. The absorbance of the solution wells was read at 550 nm. Absorbance 
values were normalized to DMSO-containing control wells and plotted as the concentration 
of test compound versus % cell viability. IC50 values were interpolated from the resulting 
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dose dependent curves. The reported IC50 values are the average from at least three 
independent experiments, each of which consisted of six replicates per concentration level.
For specific cell death inhibitor assays, inhibitors of necroptosis (necrostatin-1, 60 μM), 
H2O2-induced necrosis (IM-54, 10 μM), apoptosis (v-VAD-FMK, 5 μM) were added to cells 
and incubated for 1 h prior to treatment with the test compounds.
Reactivity of 1 and 2 with necrostatin-1
Mixing the rhenium(V)-oxo complexes (1 and 2) (20 μM) with necrostatin-1 (60 μM) in 
DMSO and cell culture media (DMEM, RPMI, and McCoy’s 5A) did not result in a 
precipitate. Incubation of the rhenium(V)-oxo complexes (1 and 2) with necrostatin-1 (1:3 
ratio) for up to 6 hr in DMSO-d6 did not lead to a chemical reaction, as determined by 1H 
NMR analysis (Figure S11 and S12). Despite the presence of sulfur and nitrogen atoms in 
necrostatin-1, the 1H NMR spectra unequivocally prove that the reactivity/bioactivity of 1 
and 2 is not compromised by necrostatin-1.
Intracellular ROS Assay
Untreated and treated A549 cells (1.5 × 106 cells/ well) grown in 6-well plates were 
incubated with 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (20 μM) for 30 min. 
The cells were then washed with PBS (1 mL × 3), harvested, and analyzed by using the 
FACSCalibur-HTS flow cytometer (BD Biosciences) (20,000 events per sample were 
acquired). The FL2 channel was used to assess intracellular ROS levels. Cell populations 
were analyzed using the FlowJo software (Tree Star).
JC-1 Assay
The JC-1 Mitochondrial Membrane Potential Assay Kit (Cayman) was used. The 
manufacturer’s protocol was followed to carry out this experiment. Briefly, to untreated and 
treated A549 cells (1.5 × 106 cells/ well) grown in 6-well plates was added the JC-1 staining 
solution (100 μL/ mL of cell media). The cells were incubated for 30 min, harvested, and 
analyzed by using the FACSCalibur-HTS flow cytometer (BD Biosciences) (20,000 events 
per sample were acquired). The FL2 channel was used to assess mitochondrial 
depolarization. Cell populations were analyzed using the FlowJo software (Tree Star).
Propidium Iodide Uptake
Untreated and treated A549 cells (1.5 × 106 cells/ well) grown in 6-well plates, were washed 
with PBS (1 mL × 3), harvested, incubated with propidium iodide (5 μM), and analyzed by 
using the FACSCalibur-HTS flow cytometer (BD Biosciences) (20,000 events per sample 
were acquired). The FL2 channel was used to assess intracellular PI uptake. Cell populations 
were analyzed using the FlowJo software (Tree Star).
Fluorescence Microscopy
A549 cells (1.5 × 106 cells/ well) were incubated with and without 1 and 2 (20 μM) for 12 h. 
The media were then removed and the cells were washed with additional media (2 mL × 2). 
After incubation of the cells with more media containing Hoechst 33258 (7.5 μM) and 
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propidium iodide (5 μM), the nuclear regions were imaged using a fluorescent microscope. 
Fluorescence imaging experiments were performed using a Zeiss Axiovert 200M inverted 
epifluorscence microscope with a Hamamatsu EM-CCD digital camera C9100 and a MS200 
XY Piezo Z stage (Applied Scientific Instruments, Inc.). An X-Cite 120 metal halide lamp 
(EXFO) was used as the light source. Zeiss standard filter sets 49 was employed for imaging 
the nuclear region. The microscope was operated with Volocity software (version 6.01, 
Improvision). The exposure time for acquisition of fluorescence images was kept constant 
for each series of images at each channel.
Immunoblotting Analysis
A549 cells (1.5 × 106 cells/ well) grown in 6-well plates were incubated with 1 and 2 
(concentrations, μM) for 72 h at 37 °C. Cells were washed with PBS, scraped into SDS-
PAGE loading buffer (64 mM Tris-HCl (pH 6.8)/ 9.6% glycerol/ 2% SDS/ 5% β-
mercaptoethanol/ 0.01% Bromophenol Blue), and incubated at 95 °C for 10 min. Whole cell 
lysates were resolved by 4–20 % sodium dodecylsulphate polyacylamide gel electrophoresis 
(SDS-PAGE; 200 V for 25 min) followed by electrotransfer to polyvinylidene difluoride 
membrane, PVDF (350 mA for 1 h). Membranes were blocked in 5% (w/v) non-fat milk in 
PBST (PBS/0.1% Tween 20) and incubated with the appropriate primary antibodies (Cell 
Signalling Technology and Santa Cruz). After incubation with horseradish peroxidase-
conjugated secondary antibodies (Cell Signalling Technology), immuno complexes were 
detected with the ECL detection reagent (BioRad) and analyzed using an Alpha Innotech 
ChemiImager™ 5500 fitted with a chemiluminescence filter.
Cell Cycle
In order to monitor the cell cycle, flow cytometry studies were carried out. A549 cells (1.5 × 
106 cells/ well) grown in 6-well plates were incubated with and without the test compounds 
for 24, 48, and 72 h at 37 °C. Cells were harvested from adherent cultures by trypsinization 
and combined with all detached cells from the incubation medium to assess total cell 
viability. Following centrifugation at 1000 rpm for 5 min, cells were washed with PBS and 
then fixed with 70% ethanol in PBS. Fixed cells were collected by centrifugation at 2500 
rpm for 3 min, washed with PBS, and centrifuged as before. Cellular pellets were re-
suspended in 50 μg/mL propidium iodide (Sigma) in PBS for nucleic acids staining and 
treated with 100 μg/mL RNaseA (Sigma). DNA content was measured on a FACSCalibur-
HTS flow cytometer (BD Biosciences) using laser excitation at 488 nm and 20,000 events 
per sample were acquired. Cell cycle profiles were analyzed using the ModFit software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
RNAi signatures derived from the treatment of Eμ-Mycp19arf−/− lymphoma cells with 1 (A) 
and 2 (B) at the LD80–90 (1 μM) concentration for each compound. The exposure time was 
72 h.
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Figure 2. 
(A) IC50 values (in μM) of 1, 2, etoposide, and cisplatin against A549 cells in the absence 
and presence of apoptosis inhibitor, z-VAD-FMK (5 μM) after 72 h incubation. (B) IC50 
values (in μM) of 1 and 2 against A549 cells in the absence and presence of H2O2-induced 
necrosis inhibitor, IM-54 (10 μM), and necroptosis inhibitor, necrostatin-1 (60 μM) after 72 
h incubation. Student’s t-test, p < 0.05 or 0.01. Error bars represent standard deviations.
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Figure 3. 
(A) Representative histograms displaying the green fluorescence emitted by DCFH-DA 
stained A549 cells (red) and A549 cells treated with 1 (20 μM for 12 h) (blue) or 1 (20 μM 
for 12 h) with nectrostatin-1 (60 μM for 12 h) (orange). (B) Representative histograms 
displaying the green fluorescence emitted by DCFH-DA stained A549 cells (red) and A549 
cells treated with 2 (20 μM for 12 h) (blue) or 2 (20 μM for 12 h) with nectrostatin-1 (60 μM 
for 12 h) (orange). (C) Representative histograms displaying the green fluorescence emitted 
by DCFH-DA stained A549 cells (red) and A549 cells treated with H2O2 (1 mM for 1 h) 
(blue). (D) Representative histograms displaying the green fluorescence emitted by DCFH-
DA stained A549 cells (red) and A549 cells treated with shikonin (20 μM for 12 h) (blue).
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Figure 4. 
Fluorescence microscopy images of A549 cells untreated (A) and treated with 1 (20 μM for 
12 h) (B), 2 (20 μM for 12 h) (C), necrostatin-1 (60 μM for 12 h) (D), 1 and necrostatin-1 
(E), and 2 and necrostatin-1 (F) and then stained with Hoechst 33258 and PI. Arrows 
indicate signs of cell membrane disintegration. Scale bar = 21 μM.
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Figure 5. 
(A) IC50 values (in μM) of 1 and 2 against MEFs PARP-1+/+ and MEFs PARP-1−/− cells 
after 72 h incubation. (B) IC50 values (in μM) of 1 and 2 against HCT116 p53+/+ and 
HCT116 p53−/− cells after 72 h incubation.
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Scheme 1. 
Reaction scheme for preparing rhenium(V) oxo complexes, 1 and 2.
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Table 1
IC50 values (nM) of 1, 2, and cisplatin against various cancerous and healthy cell lines after 72 h exposure. 
The errors represent standard deviations.
Cell line Cancer type 1 2 cisplatin
A549 Lung carcinoma 207 ± 4 157 ± 15 3230 ± 467
HeLa Cervical adenocarcinoma 445 ± 43 695 ± 21 4100 ± 113
U2OS Bone osteosarcoma 274 ± 6 209 ± 31 4600 ± 600 a
NTERA-2 Testis carcinoma 230 ± 28 255 ± 35 385 ± 49
A2780 Ovarian carcinoma 670 ± 40 150 ± 10 700 ± 200 a
A2780CP70 Ovarian carcinoma 42 ± 15 56 ± 2 8415 ± 205
MRC-5 Lung fibroblast 1351 ± 228 709 ± 76 5300 ± 600 a
a
IC50 values taken from Ref. 46.
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Table 2
IC50 values (nM) of 1, 2, and cisplatin against a panel of cisplatin-resistant cell lines and quiescent lung 
carcinoma A549 cells after 72 h exposure. The errors represent standard deviations.
Cell line Cancer type 1 2 cisplatin
HT-29 Colorectal adenocarcinoma 85 ± 11 95 ± 20 29640 ± 1329
MDA-MB-231 Breast adenocarcinoma 475 ± 161 1735 ± 275 43600 ± 7071
MCF-7 Breast adenocarcinoma 285 ± 35 805 ± 21 9740 ± 537
PC-3 Prostate adenocarcinoma 270 ± 14 780 ± 10 10250 ± 919
DU 145 Prostate carcinoma 2840 ± 381 1370 ± 84 > 100000
A549 (quiescent) Lung carcinoma 8610 ± 749 5245 ± 1986 9420 ± 1937
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